Polymer Therapeutics

POLYMER THERAPEUTICS for Drug Delivery

.

circle-arrow-right Polymers as

Door Openers

Discover our polymer products suitable for drug delivery including poly(ethyleneglycol) s (PEGs), poly(amino acid)s (PArg, PGlu, PLys, POR, PSar), poly(oxazoline)s, as well as lipidated polymers and co-polymers. pages 1-3

Poly(ethylene glycol)s -

Innovative (co)polymers based

Benefit of our services -

oldies but goldies.

on poly(amino acid)s and po-

let us be your partner!

page 1

ly(oxazoline)s. page 2,3

page 4 Version: IF20_2

Polymer Therapeutics

Polymer Therapeutics for Drug Delivery Poly(ethylene glycol)s Small drug molecules like peptides and other biomolecules have high potential as drugs due to their specificity and efficacy in combination with low side effects. However, they suffer from rapid clearance from the human body and show poor pharmacokinetic properties which limits their applications. Due to the fact that such biomolecules are similar to biological components, they are easily attacked by the immune system of the body, i.e. by antibodies and degradation enzymes. Another limitation might be insufficient solubility. Thus, many promising novel drug molecules will never reach market approval.

Attaching polymers which are tolerated by the physiologic systems, such as poly(amino acids), poly(ethylene glycol)s or other variants improves drastically their bioavailability and biodistribution and turns sensitive biomolecules into robust drugs. First attempts with polymers were made already in the 1960s – either by attaching the therapeutic agent covalently to a polymer or by entrapping it non-covalently in a polymer nanoparticle. Over the years, polymers have garnered attention in the evolution of drug delivery technologies for both water-soluble and hydrophobic drug molecules.

Pharmacokinetic properties of a PEGylated drug in comparison with a non-PEGylated drug.

The first polymer-drug conjugates that showed promising results contained poly(ethyleneglycol) (PEG).

The pharmacological effects of PEG and many other first generation polymer attachments are mainly of physical nature. They act solubilizing due to their hydrophilicity, prevent degradation, and reduce immunogenicity by shielding the pharmaceutical and prevent excretion by increasing the hydrodynamic radius.

Iris Biotech offers a portfolio of a thousand different PEG chemicals with a length ranging from only two ethylenglycol units (with a molecular weight around 100 g/mol) up to long chain PEGs of molecular weights beyond 20,000 g/mol. Further to this standard portfolio, we can produce for you also customized PEG variants according to your personal needs.

1

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Poly(amino acid)s Eventhough PEGs still represent the most frequently used polymer for drug delivery, several possible side effects and complications are reported for this type of polymer, e.g. non-biodegradability/accumulation and immunogenicity. Besides, growing knowledge on drug delivery technologies allows to create “intelligent” systems which can help transporting a payload to a target destination or even to destinations where it could not go without the polymer’s help. Biodegradable poly(amino acid)s appear very attractive in this context. However, their availability in sufficient quality and quantity for broad pharmaceutical application was a bottleneck in the first years.

At Iris Biotech, we are presenting biodegradable and biocompatible poly(amino acid)s (PArg, PGlu, PLys, POr, PSar) as well as poly(oxyzolines) as polymers for drug delivery.

General chemical structures of poly(amino acid)s and POx available at Iris Biotech.

Poly(sarcosines) have been employed in a number of drug delivery systems and are gaining increasing attention. Iris Biotech offers monofunctional, homo- and heterobifunctional poly(sarcosines) with a wide variety of functional groups. Degrees of polymerization (n) may range from below 10 to above 1,000.

Thus, molar masses of approx. 1 kg/mol to 100 kg/mol are feasible.

The use of poly(sarcosines) with functional head- and tail-groups for bioconjugation is comparable to the well-known PEGylation technology. In a study, a poly(sarcosine)- and PEG-conjugated Uricase were compared, and it was shown that the PSar conjugation is efficient in extending Uricase half-life in vivo more than 20-fold. Furthermore, PSar-Uricase is less immunogenic compared to either native or PEGylated Uricase in vivo, and polysarcosination did not affect the enzymatic activity.

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

2

Polymer Therapeutics Polymer-Lipid Conjugates

Case Study Uricase: PEGylation vs. Polysarcosination.

Almost all polymers discussed by now are water soluble – for good reason: most drug delivery systems are designed to transport their payload in the bloodstream and thus they must be highly water soluble.

However, once the delivery complex has reached its destination, the picture turns to the opposite: if a cargo should enter a cell through the cell membrane (which mainly consists of a hydrophobic lipid bilayer), a highly hydrophilic transport system is rather counterproductive. Here, a lipophilic moiety should rather be helpful. Therefore, many drug delivery systems also contain hydrophobic blocks that help to form barrier-overbearing nanostructures such as micelles, liposomes, or lipid nanoparticles (LNPs).

Especially in the curse of the worldwide Corona pandemic, the development of mRNA vaccines emphasized the importance of tools for secured RNA delivery as they themselves are unable to cross physiological barriers and are susceptible to enzymatic degradation by endogenous nucleases. Thus, for successful RNA drug delivery, polymer-conjugated lipid nanoparticles (LNPs) capable to permeate plasma membranes are reported in literature.

PGA Lipid combinations available at Iris Biotech. For more information, see related products.

3

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

PSar Lipid combinations available at Iris Biotech. For more information, see related products.

Copolymers Another attractive feature of the polymers presented is the fact that they can be combined with each other to form different types of copolymers, e.g. grafted polymers, random copolymers or block copolymers. This allows us to modify parameters such as size, conformation, charge, solubility, geometry, and topoplogy and opens a toolbox to an almost unlimited number of combinations specifically tailored to your particular needs.

Services Benefit of our services! Formulation of multiple bench-scale samples from 1-5 ml and scaling up from 0,2-5 l are available. Formulation services are mainly focused on the support of client-based screening assays and scale up. These services include optimization of key process parameters such as molar ratios, mixing flow rates, concentration, and flow speed.

Our scientists support the development of polymer therapeutic substances and their analysis through the entire project life cycle from first R&D batches through pre-clinical material to final GMP- & GLPcertified commercial production and testing. Equipment and skills are specially suited but not limited to method development, validation, and stability studies.

Poly-Arginines Product details

PAR1060

nBu-PArg(20)*HCl

n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight

O

26982-20-7 3800 Da

N H

(S)

H 20

HCl

HN HN

H N

NH2

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

4

Polymer Therapeutics Product details

PAR1020

nBu-PArg(50)*HCl

n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight

O

26982-20-7 9600 Da

(S)

N H

HCl

HN NH2

nBu-PArg(100)*HCl

n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight

O

26982-20-7 19000 Da

(S)

N H

H

HCl NH2

nBu-PArg(200)*HCl

n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight

H N

100

HN HN

PAR1050

H 50

HN

PAR1030

H N

O

26982-20-7 38500 Da

(S)

N H

H 200

HCl

HN HN

H N

NH2

Poly-Glutamic Acids Product details

PGA1005

nBu-PGA(20)

n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight

26247-79-0 3000 Da

O (S)

N H

H N

O- Na+

O

PGA1010

nBu-PGA(50)

n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight

26247-79-0 7500 Da

O N H

(S)

H N

H 50

O

5

H 20

O- Na+

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Product details

PGA1015

nBu-PGA(100)

n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight

O

26247-79-0 15100 Da

H N

(S)

N H

H 100

O- Na+

O

PGA1020

nBu-PGA(200)

n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight

O

26247-79-0 30200 Da

H N

(S)

N H

H 200

O- Na+

O

PGA1085

Prg-PGA(20)

Propargyl-poly(L-glutamic acid) sodium salt Mol. weight

3000 Da

O (S)

N H

H N

O- Na+

O

PGA1090

Prg-PGA(50)

Propargyl-poly(L-glutamic acid) sodium salt Mol. weight

7500 Da

O (S)

N H

H N

O- Na+

Prg-PGA(100)

Propargyl-poly(L-glutamic acid) sodium salt Mol. weight

15000 Da

O (S)

N H

H N

O- Na+

Prg-PGA(200)

Propargyl-poly(L-glutamic acid) sodium salt Mol. weight

H 100

O

PGA1100

H 50

O

PGA1095

H 20

30200 Da

O N H

(S)

H N

H 200

O

O- Na+

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

6

Polymer Therapeutics Product details

PGA1125

N3 -PGA(20)

Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight

3000 Da

O N3

O

(S)

N H

3

H N

O- Na+

O

PGA1130

N3 -PGA(50)

Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight

7500 Da

O N3

O

(S)

N H

3

H N

O- Na+

N3 -PGA(100)

Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight

15000 Da

O N3

O

(S)

N H

3

H N

O- Na+

N3 -PGA(200)

Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight

30000 Da

O N3

O

(S)

N H

3

H N

O- Na+

nBu-PGA(20)[Prg(20)]

n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight

3000 Da

O (S)

N H

(S)

x

O

N H

H 20 - x

NH

7500 Da

O- Na+

O O N H

O

7

H N

nBu-PGA(50)[Prg(20)]

n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight

O- Na+

O

O

PGA1195

H 200

O

PGA1190

H 100

O

PGA1140

H 50

O

PGA1135

H 20

(S)

H N

(S)

x

O

N H

H 50 - x

NH

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Product details

PGA1200

nBu-PGA(100)[Prg(20)]

n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight

15000 Da

O (S)

N H

30000 Da

100 - x

O- Na+

O O (S)

N H

H N

(S)

x

O

H

N H

200 - x

NH

nBu-PGA(20)[PEG2-N3(20)]

n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight

H

N H

NH

O

PGA1290

(S)

O

nBu-PGA(200)[Prg(20)]

n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight

H N x

O

PGA1205

O- Na+

O

3600 Da

O- Na+

O O (S)

N H

H N

(S)

x

O

H

N H

20 - x

NH

O

O 3

PGA1295

nBu-PGA(50)[PEG2-N3(20)]

n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight

9100 Da

O- Na+

O O (S)

N H

H N

(S)

x

O

H

N H

50 - x

NH

O

O 3

PGA1300

18300 Da

O- Na+

O O (S)

N H

H N

(S)

x

O

H

N H

100 - x

NH

O

O 3

PGA1305

N3

nBu-PGA(200)[PEG2-N3(20)]

n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight

N3

nBu-PGA(100)[PEG2-N3(20)]

n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight

N3

36700 Da

O- Na+

O O N H

O

(S)

H N

(S)

x

O

H

N H

200 - x

NH O 3

N3

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

8

Polymer Therapeutics Product details

PGA1490

nBu-PGA(20)[mPEG(20)]

n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight

O- Na+

O O (S)

N H

4300 Da

H N

(S)

x

O

H

N H

20 - x

NH

O

O 6

PGA1495

nBu-PGA(50)[mPEG(20)]

n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight

O- Na+

O O (S)

N H

10900 Da

H N

(S)

x

O

H

N H

50 - x

NH

O

O 6

PGA1500

O- Na+

O O (S)

N H

21800 Da

H N

(S)

x

O

H

N H

100 - x

NH

O

O 6

PGA1505

O- Na+

O O N H

40600 Da

O

(S)

H N

(S)

x

O

H

N H

200 - x

NH O 6

PGA1700

OMe

Aldehyde-PGA(20)tBu

(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight

OMe

nBu-PGA(200)[mPEG(20)]

n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight

OMe

nBu-PGA(100)[mPEG(20)]

n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight

OMe

3000 Da

O O O

(S)

N H

H N 20

O- Na+

O

PGA1710

Aldehyde-PGA(50)tBu

(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight

7600 Da

O O O

N H

(S)

H N 50

O

9

O

O O- Na+

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Product details

PGA1720

Aldehyde-PGA(100)tBu

(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight

15100 Da

O O O

H N

(S)

N H

100

O- Na+

O

PGA1740

Aldehyde-PGA(200)tBu

(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight

30200 Da

O O

H N

(S)

N H

O

200

nBu-PGA(20)[Hyd(20)]

n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight

O O- Na+

O

PGA1810

O

O (S)

N H

3700 Da

O- Na+

O

H N

(S)

x

O

N H

H 20 - x

NH

O

HN

O O

PGA1770

nBu-PGA(100)[Hyd(20)]

n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20 mol% substitution, MW 20200Da) Mol. weight

O (S)

N H

20200 Da

O- Na+

O

H N

(S)

x

O

N H

H 100 - x

NH

O

HN

O O

PGA1830

nBu-PGA(200)[Hyd(20)]

n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight

O (S)

N H

40100 Da

O- Na+

O

H N

(S)

x

O

N H

H 200 - x

NH

O

HN

O O

PGA1870

nBu-PGA(50)[Hyd(20)]

n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight

9900 Da

O- Na+

O O N H

O

(S)

H N

(S)

x

O

N H

H 50 - x

NH HN

O O

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

10

Polymer Therapeutics Product details

PGA1880

C14-[PGA(DIOL)]10 -H

(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight

O

H N

(S)

N H

H 10

2000 Da

O

NH

HO

HO

PGA1890

C14-[PGA(DIOL)]20 -H

(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight

O

H N

(S)

N H

H 20

4000 Da

O

NH

HO

HO

PGA1900

C14-[PGA(DIOL)]10 -COCH3

(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight

O

H N

(S)

N H

10 O

2000 Da O

NH

HO

HO

PGA1910

C14-[PGA(DIOL)]20 -COCH3

(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight

O N H

4000 Da

H N

(S)

20

O

O

NH

HO

HO

PGA1920

DMPE-[PGA(DIOL)]30 -H

(1,2-Dimyristoyl-glycero-3-phosphoethanolamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide) acetamide Mol. weight

7000 Da

O O O O

(R)

O

OH P O

O O

N H

(S)

H 30

O HO

HO

11

H N

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

NH

Poly-Lysines Product details

PLY1030

nBu-PLys(20)*HCl

n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight

O

26124-78-7 3300 Da

(S)

N H

H N

H 20

HCl NH2

PLY1031

nBu-PLys(20)*HBr

n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight

O

26124-78-7 4200 Da

(S)

N H

H N

H 20

HBr NH2

PLY1001

nBu-PLys(50)*HBr

n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight

O

26124-78-7 10500 Da

(S)

N H

H N

H 50

HBr NH2

PLY1010

nBu-PLys(100)*HCl

n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight

O

26124-78-7 16000 Da

(S)

N H

H N

H 100

HCl NH2

PLY1011

nBu-PLys(100)*HBr

n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight

O

26124-78-7 20900 Da

N H

(S)

H N

H 100

HBr NH2

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

12

Polymer Therapeutics Product details

PLY1020

nBu-PLys(200)*HCl

n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight

O

26124-78-7 32500 Da

H N

(S)

N H

H 200

HCl NH2

PLY1021

nBu-PLys(200)*HBr

n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight

O

26124-78-7 42000 Da

(S)

N H

H N

H 200

HBr NH2

Poly-Ornithines Product details

POR1060

nBu-POR(20)*HCl

n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight

O

26982-21-8 3000 Da HCl

POR1020

O

26982-21-8 5800 Da

H N

H 50

H2N

nBu-POR(100)*HCl O

26982-21-8 15000 Da

N H

HCl

13

(S)

N H

n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight

H 20

nBu-POR(50)*HCl

HCl

POR1030

H N

H2N

n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight

(S)

N H

(S)

H N

H 100

H2N

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Product details

POR1040

nBu-POR(150)*HCl

n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight

O

26982-21-8 22600 Da HCl

POR1050

H N

H 150

H2N

nBu-POR(200)*HCl

n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight

(S)

N H

O

26982-21-8 30100 Da

(S)

N H

HCl

H N

H 200

H2N

Poly-Sarcosines Product details

PSR1740

Mal-PSar-OMe (5 kDa)

N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide

O O

N

N

OMe

nH

O

PSR1750

N

O

Mal-PSar-OMe (10 kDa)

N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide

O O

N

N

OMe

nH

O

PSR1760

N

O

Mal-PSar-OMe (15 kDa)

N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide

O O

N

N

OMe

nH

O

N

O

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

14

Polymer Therapeutics Product details

PSR1770

NHS-PSar-OMe (5 kDa)

N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide

O O

N

N

N

OMe

nH

O

O

O

O

PSR1780

NHS-PSar-OMe (10 kDa)

N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide

O O

N

N

N

OMe

nH

O

O

O

O

PSR1790

NHS-PSar-OMe (15 kDa)

N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide

O O

N

N

N

OMe

nH

O

O

O

O

PSR1830

VitE-PSar10

N-alpha-isopropyl polysarcosine(10) N-omega-(Vitamine E)-4-oxobutanoate Mol. weight

O N

N H

O 10

1300 Da

O

O

O

PSR1820

VitE-PSar20

N-alpha-isopropyl polysarcosine(20) N-omega-(Vitamine E)-4-oxobutanoate Mol. weight

2000 Da

O N H

N

O 20

O

O

O

15

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Poly-Oxazolines Product details

POX1200

Me-PMeOx(50)-N3

alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight

Me

26375-28-0 CH3 (C 4H7NO)50N3 4300 Da

O

POX1210

Me

26375-28-0 CH3 (C 4H7NO)100N3 8500 Da

Me

100 Me

Me-PEtOx(50)-N3

alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight

25805-17-8 CH3 (C 5H9NO)50N3 5000 Da

POX2210

Me-PEtOx(100)-N3

Me

CAS-No. Formula Mol. weight

25805-17-8 CH3 (C 5H9NO)100N3 5000 Da

POX1220

Me-PMeOx(50)-NH2*HCl

alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-amine hydrochloride 26375-28-0 CH3 (C 4H7NO)50NH2*HCl 4300 Da

N

N3 50

O

alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-azide

CAS-No. Formula Mol. weight

N3

N

O

POX2200

50

Me-PMeOx(100)-N3

alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight

N3

N

Me

N

N3 100

O

Me

O

NH3+Cl-

N

50 Me

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

16

Polymer Therapeutics Product details

POX1230

Me-PMeOx(100)-NH2*HCl

alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight

26375-28-0 CH3 (C 4H7NO)100NH2*HCl 8500 Da

POX2220

Me-PEtOx(50)-NH2*HCl

Me

O

alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight

25805-17-8 CH3 (C 5H9NO)50NH2*HCl 5000 Da

POX2230

Me-PEtOx(100)-NH2*HCl 25805-17-8 CH3 (C 5H9NO)100NH2*HCl 10000 Da

POX1240

Me-PMeOx(50)-COOH

alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-succinamic acid CAS-No. Formula Mol. weight

26375-28-0 CH3 (C 4H7NO)50COCH2CH2COOH 4300 Da

POX1241

HOOC-PMeOx(50)-Pip

alpha-Carboxymethyl-poly(2-methyl-2-oxazoline)-omega-Piperidine Formula Mol. weight

HOOCCH2 (C 4H7NO)50NC 6H12 4300 Da

POX2241

HOOC-PEtOx(50)-Pip

alpha-Carboxymethyl-poly(2-ethyl-2-oxazoline)-omega-piperidine Formula Mol. weight

17

HOOC-CH2 (C 5H9NO)50NC 6H12 5000 Da

100 Me

Me

NH3+Cl-

N

50

O

alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight

NH3+Cl-

N

Me

NH3+Cl-

N

100

O

Me

N

O

O

H N 50 Me

HO

OH O

N

N O

O

HO

N O

50 Me

N 50

O

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

Product details

POX1250

HOOC-PMeOx(50)-N3

alpha-Carboxymethyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight

26375-28-0 HOCOCH2 (C 4H7NO)50N3 4300 Da

POX2250

HOOC-PEtOx(50)-N3

alpha-Carboxymethyl-poly(2-ethyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight

25805-17-8 HOCOCH2 (C 5H9NO)50N3 5000 Da

HO

N3

N O

O

HO

Me

N O

50

N3 50

O

References: → Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers; Z. Niu, E. Tedesco, F. Benetti, A. Mabondzo, I. M. Montagner, I. Marigo, D. Gonzalez-Touceda, S. Tovar, C. Diéguez, M. J. Santander-Ortega, M. J. Alonso; Journal of Controlled Release 2017; 263: 4-17. https://doi.org/10.1016/j.jconrel.2017.02.024 → Polyarginine nanocapsules: a new platform for intracellular drug delivery; M. V. Lozano, G. Lollo, M. Alonso-Nocelo, J. Brea, A. Vidal, D. Torres, M. J. Alonso; Journal of Nanoparticle Research 2013; 15: 1515. https://doi.org/10.1007/s11051-013-1515-7 → Suppressive immune response of poly-(sarcosine) chains in peptide-nanosheets in contrast to polymeric micelles; E. Hara, M. Ueda, C. J. Kim, A. Makino, I. Hara, E. Ozeki, S. Kimura; J. Pept. Sci. 2014; 20: 570-577. https://doi.org/10.1002/psc.2655 → Thermoresponsive release from poly(Glu(OMe))-block-poly(Sar) microcapsules with surface-grafting of poly(N-isopropylacrylamide); T. Kidchob, S. Kimura, Y. Imanishi; J. Control. Release 1998; 50: 205-14. https://doi.org/10.1016/s0168-3659(97)00135-1 → Amphiphilic poly(Ala)-b-poly(Sar) microspheres loaded with hydrophobic drug; T. Kidchob, S. Kimura, Y. Imanishi; J. Control. Release 1998; 51: 241-248. https://doi.org/10.1016/s0168-3659(97)00176-4 → On the biodegradability of polyethylene glycol, polypeptoids and poly(2-oxazoline)s; J. Ulbricht, R. Jordan, R. Luxenhofer; Biomaterials 2014; 35: 4848-4861. https://doi.org/10.1016/j.biomaterials.2014.02.029 → Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation; Y. Hu, Y. Hou, H. Wang, H. Lu; Bioconjugate Chem. 2018; 29(7): 2232-2238. https://doi.org/10.1021/acs.bioconjchem.8b00237 → Polysarcosine-containing copolymers: Synthesis, characterization, self-assembly, and applications; A. Birke, J. Ling, M. Barz; Prog. Polym. Sci. 2018; 81: 163-208. https://doi.org/10.1016/j.progpolymsci.2018.01.002 → Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery; S. S. Nogueira, A. Schlegel, K. Maxeiner, B. Weber, M. Barz, M. A. Schroer, C. E. Blanchet, D. I. Svergun, S. Ramishetti, D. Peer, P. Langguth, U. Sahin, H. Haas; ACS Appl. Nano Mater. 2020; 3(11): 10634-10645. https://doi.org/10.1021/acsanm.0c01834 → Polyamide/Poly(Amino Acid) Polymers for Drug Delivery; S. H. S. Boddu, P. Bhagav, P. K. Karla, S. Jacob, M. D. Adatiya, T. M. Dhameliya, K. M. Ranch, A. K. Tiwari; J. Funct. Biomater. 2021; 12(4): 58. https://doi.org/10.3390/jfb12040058

Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation

18

Empowering Peptide Innovation